Please assess the completion status of the following clinical trial:

Trial Title: Phytosterols, Ezetimibe, and Cholesterol Metabolism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female of any race or ethnicity between 18 to 80 years of age;~* Body mass index between 20 - 35 kg/m2;~* LDL-cholesterol between 130 - 189 mg/dL based on the average of duplicate screening measures. If the two LDL-C levels differ by more than 30 mg/dL, a third test will be scheduled with all three results averaged;~* Free of chronic disease;~* Willing to eat only the foods that are provided by the Center during the diet periods;~* Willing to abstain from the consumption of alcohol for 48-hours prior to blood draw days;~* Willing to drink no more than 5 cups of caffeine-containing beverages a day.~Exclusion Criteria:~* Age \< 18 or \> 80 years;~* Based on duplicate screening laboratory values: 1)LDL-C \>=190 mg/dL; 2)TG \>=250 mg/dL;3)blood pressure \>= 160 mm Hg systolic or 95 mm Hg diastolic;~* Documented presence of atherosclerotic disease;~* Diabetes mellitus;~* Renal, hepatic, endocrine, gastrointestinal, hematological or other systemic disease;~* Body mass index \> 35;~* For women, pregnancy, breast feeding or postpartum \< 6 months;~* For women, peri-menopausal;~* For women, sexually active but not practicing effective birth control methods;~* History of drug or alcohol abuse;~* History of depression or mental illness requiring treatment or medication within the last 6 months;~* multiple food allergies or significant food preferences or restrictions that would interfere with diet adherence;~* Chronic use of over-the-counter medication which would interfere with study endpoints including laxatives and antacids;~* Lifestyle or schedule incompatible with the study protocol;~* Planned continued use of dietary supplements through the study trial;~* Taking any lipid-lowering, or other medications known to affect blood cholesterol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Crossover order ABC (Type: EXPERIMENTAL): The order of treatments is A (phytosterols + ezetimibe), B (double placebo), and C (active ezetimibe and phytosterol placebo).
- Crossover order BCA (Type: EXPERIMENTAL): The order of treatments is B (double placebo), C (active ezetimibe and phytosterol placebo), and A (phytosterols + ezetimibe).
- Crossover order BAC (Type: EXPERIMENTAL): The order of treatments is B (double placebo), A (phytosterols + ezetimibe), and C (active ezetimibe and phytosterol placebo)
- Crossover order ACB (Type: EXPERIMENTAL): The order of treatments is A (phytosterols + ezetimibe), C (active ezetimibe and placebo phytosterols, and B (double placebo).
- Crossover order CAB (Type: EXPERIMENTAL): The order of treatments is C (active ezetimibe and placebo phytosterols), A (phytosterols + ezetimibe), and B (double placebo).
- Crossover order CBA (Type: EXPERIMENTAL): The order of treatments is C (active ezetimibe and placebo phytosterols), B (double placebo), and A (phytosterols and ezetimibe).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete